Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Enthera and Trianni Announce Licensing Agreement


SAN FRANCISCO and MILANO, Italy, March 22, 2018 /PRNewswire/ -- Trianni, Inc. ("TRIANNI") and Enthera, S.r.L. ("ENTHERA") jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mousetm, a best-in-class monoclonal antibody discovery platform.

Trianni incorporated recent advances in DNA synthesis and genomic modification technology to develop its optimized therapeutic monoclonal antibody discovery platform.

"TRIANNI is pleased to add ENTHERA as an important new licensee," stated Dr. David Meininger, TRIANNI's Chief Business Officer. "TRIANNI continues to innovate to the benefit of our growing list of partners. We're excited to enable ENTHERA's antibody discovery efforts through this agreement."

"We are confident that the access to TRIANNI's technology will dramatically improve our discovery efforts. It is a real pleasure entering into this collaboration," declared Prof. Paolo Fiorina, Chief Scientific Officer at Enthera.

No financial details were disclosed.

About Trianni, Inc.
Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI's lead technology, The Trianni Mousetm, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. TRIANNI's transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-in-class therapeutic antibody discovery platform.  The company is headquartered in San Francisco, CA. Additional information about TRIANNI is available through its corporate website, www.trianni.com.

About Enthera, S.r.L.
Enthera S.r.l. is a new Italian biotech start-up which mission is to find new therapeutic approaches to treat diabetes and related gastrointestinal complication (enteropathy), as well as other intestinal disorders sharing the same biological pathway. Its name comes from the crasis of the terms entero (referring to the intestine) and therapy.  

Enthera was founded by BiovelocITA in October 2016 in collaboration with the scientists: Prof. Paolo Fiorina and Dr. Francesca D'Addio.

Contacts: TRIANNI
Mandy Boyd
Director of Marketing
1.415.231.0256 [o]
1.866.674.9314
[email protected]

SOURCE Trianni, Inc.


These press releases may also interest you

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...

4 mai 2024
Women's Heart Health Month is recognized every May and is focused on raising awareness about cardiovascular health among women. It aims to educate women about the risks, symptoms, and prevention of heart disease, which is the leading cause of death...

4 mai 2024
RaySearch Laboratories AB (publ) and C-RAD are pleased to announce a collaboration agreement, aiming at jointly developing innovative solutions and products to enhance the quality of radiation therapy. The focus of the collaboration is to...

4 mai 2024
SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility...

4 mai 2024
Scientology Network's VOICES FOR HUMANITY, the weekly series presenting heroic change makers from a variety of faiths, cultures and nations, working to uplift their communities, announces a new episode featuring anti-drug activist Robert Galibert....



News published on and distributed by: